<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05790564</url>
  </required_header>
  <id_info>
    <org_study_id>LPI-2022-1435</org_study_id>
    <nct_id>NCT05790564</nct_id>
  </id_info>
  <brief_title>Almonds to Improve Gut Health and Decrease Inflammation</brief_title>
  <official_title>Almonds to Improve Gut Health and Decrease Inflammation in Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oregon State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Almonds are a good source of beneficial compounds. This study will investigate if eating&#xD;
      almonds everyday for 12 weeks can affect gut health and inflammation in persons with&#xD;
      metabolic syndrome. Investigators will measure changes in metabolism, heart health, and the&#xD;
      levels of vitamins and other compounds from almonds.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Metabolic Syndrome (MetS) affects over a billion people world-wide. MetS progression and&#xD;
      further health complications are driven by chronic inflammation. Major causes of inflammation&#xD;
      in MetS are gut barrier breakdown and the absorption of harmful bacteria. What causes the gut&#xD;
      barrier breakdown is not clear, but a poor diet, especially low micronutrient intakes like&#xD;
      vitamin E, is implicated by propagating a vicious cycle that promotes oxidative stress,&#xD;
      inflammation and further gut barrier damage. This study will assess the impact of daily&#xD;
      consumption of 2 ounces of almonds for 12 weeks on gut health, markers of inflammation and&#xD;
      cardiometabolic health, and micronutrient status in persons with MetS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 17, 2022</start_date>
  <completion_date type="Anticipated">July 2025</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gut permeability and health: Serum endotoxin</measure>
    <time_frame>0 and 4 weeks</time_frame>
    <description>Change from baseline at week 4: Marker of gut barrier function and health, serum endotoxin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gut permeability and health: Short chain fatty acids</measure>
    <time_frame>0 and 4 weeks</time_frame>
    <description>Change from baseline at week 4: Markers of gut barrier function and health fecal short chain fatty acids profiles</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gut permeability and health: Inflammatory biomarkers</measure>
    <time_frame>0 and 4 weeks</time_frame>
    <description>Change from baseline at week 4: Gut inflammatory biomarkers calprotectin and myeloperoxidase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biomarkers of inflammation</measure>
    <time_frame>0 and 4 weeks</time_frame>
    <description>Change from baseline at week 4: Plasma inflammatory markers (ex. TNF and IL-6)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxidative stress status: malondialdehyde</measure>
    <time_frame>0 and 4 weeks</time_frame>
    <description>Change from baseline at week 4: Plasma malondialdehyde</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxidative stress status: isoprostanes</measure>
    <time_frame>0 and 4 weeks</time_frame>
    <description>Change from baseline at week 4: Urinary isoprostanes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiometabolic health</measure>
    <time_frame>0 and 12 weeks</time_frame>
    <description>Change from baseline at week 12: Total cholesterol, LDL, HDL, and triglycerides</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vitamin E status</measure>
    <time_frame>0, 4 and 12 weeks</time_frame>
    <description>Change from baseline at week 4 and week 12: Plasma α-tocopherols</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vitamin E status: Urinary catabolite</measure>
    <time_frame>0, 4 and 12 weeks</time_frame>
    <description>Change from baseline at week 4 and week 12: Urinary vitamin E catabolite (α-CEHC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>0, 4 and 12 weeks</time_frame>
    <description>Change from baseline at week 4 and week 12: Systolic, and diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>0, 4 and 12 weeks</time_frame>
    <description>Change from baseline at week 4 and week 12: Weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI</measure>
    <time_frame>0, 4 and 12 weeks</time_frame>
    <description>Change from baseline at week 4 and week 12: BMI (weight and height will be combined to report BMI in kg/m^2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist circumference</measure>
    <time_frame>0, 4 and 12 weeks</time_frame>
    <description>Change from baseline at week 4 and week 12: Waist circumference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemic control: glucose</measure>
    <time_frame>0 and 12 weeks</time_frame>
    <description>Change from baseline at week 12: Fasting blood glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemic control: Insulin</measure>
    <time_frame>0 and 12 weeks</time_frame>
    <description>Change from baseline at week 12: Insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemic control: HOMA-IR</measure>
    <time_frame>0 and 12 weeks</time_frame>
    <description>Change from baseline at week 12: HOMA-IR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other almond-based bioactives (polyphenol levels)</measure>
    <time_frame>0 and 12 weeks</time_frame>
    <description>Change from baseline at week 12: Urinary metabolites of flavonoids like (+)-catechin, (-)-epicatechin and naringenin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mineral status</measure>
    <time_frame>0 and 12 weeks</time_frame>
    <description>Change from baseline at week 12: Plasma magnesium, calcium, iron, zinc, and copper (microgram/mL)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Metabolic Syndrome</condition>
  <condition>Dysbiosis</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Almonds</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daily consumption of 2 ounces of unsalted, dry roasted almonds for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crackers</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily consumption of non-whole grain crackers for 12 weeks (caloric equivalent to 2 ounces of dry roasted almonds)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Almond</intervention_name>
    <description>Daily consumption of 2 ounces of unsalted, dry roasted almonds for 12 weeks</description>
    <arm_group_label>Almonds</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Crackers</intervention_name>
    <description>Daily consumption of non-whole grain crackers for 12 weeks (caloric equivalent to 2 ounces of dry roasted almonds)</description>
    <arm_group_label>Crackers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 35-60 years&#xD;
&#xD;
          -  3 or more of the following: hypertension (systolic BP 130-179 mmHg or diastolic BP&#xD;
             85-119 mmHg); hyperglycemia (fasting glucose 100-599 mg/dL); central obesity [waist&#xD;
             circumference greater than 40.1 inches (M) or 34.6 inches (F); hypertriglyceridemia&#xD;
             (150-499 mg/dL); low HDL [lower than 40 mg/dL (M) or 50 mg/dL (F)]&#xD;
&#xD;
          -  Willing to restrict consumption of nuts other than study nuts for 1 week prior to and&#xD;
             throughout the study (13 weeks)&#xD;
&#xD;
          -  Willing to stop probiotic supplements one week prior to and during the study (13&#xD;
             weeks)&#xD;
&#xD;
          -  Willing to stop multivitamins and supplements containing vitamin E, magnesium,&#xD;
             calcium, iron, zinc and copper one week prior to and during the study (13 weeks)&#xD;
&#xD;
          -  Willing to complete intake diaries during the study&#xD;
&#xD;
          -  Willing to maintain current eating patterns (no significant diet change during study)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Weekly consumption of almonds, hazelnuts, peanuts and sunflower seeds combined greater&#xD;
             than 2 servings (about 2 oz) in the past 3 months&#xD;
&#xD;
          -  Nut, wheat, or gluten allergy/intolerance&#xD;
&#xD;
          -  Regular use of vitamin E supplements&#xD;
&#xD;
          -  Consume more than 2 alcoholic drinks daily&#xD;
&#xD;
          -  Tobacco use, including e-cigarettes, or smoking of any substance (e.g. cannabis) in&#xD;
             the past 3 months&#xD;
&#xD;
          -  Pregnancy, breastfeeding, or planning to become pregnant before completing the study&#xD;
&#xD;
          -  Vigorous exercise greater than 7 hours/week&#xD;
&#xD;
          -  History of cardiovascular disease, liver disease or cancer&#xD;
&#xD;
          -  Have had bariatric surgery (e.g. gastric bypass, gastric banding, sleeve gastrectomy,&#xD;
             etc.), other gastrointestinal procedures (e.g. cholecystectomy), disorders (e.g.&#xD;
             Crohn's disease, celiac disease, ulcerative colitis) or chronic diarrhea&#xD;
&#xD;
          -  Diagnosis of hemochromatosis&#xD;
&#xD;
          -  Chronic use (daily intake in past 30 days) of anti-inflammatory medication (steroid or&#xD;
             NSAID)&#xD;
&#xD;
          -  Use of ezetimibe or orlistat&#xD;
&#xD;
          -  Use of oral antibiotic medication within the past month&#xD;
&#xD;
          -  Body Mass Index (BMI) &lt;25.0 or &gt;35.0 kg/m2&#xD;
&#xD;
          -  Regular use of multivitamin supplements in the past 3 months&#xD;
&#xD;
          -  Physician prescribed use of probiotic, vitamin E, magnesium, calcium, iron, zinc or&#xD;
             copper supplements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura Beaver, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon State University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura Beaver, PhD</last_name>
    <phone>541-737-5049</phone>
    <email>laura.beaver@oregonstate.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sandra Uesugi, RN, BSN, MS</last_name>
    <phone>541-737-3594</phone>
    <email>lpi.research@oregonstate.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oregon State University</name>
      <address>
        <city>Corvallis</city>
        <state>Oregon</state>
        <zip>97331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Beaver, PhD</last_name>
      <phone>541-737-5049</phone>
      <email>laura.beaver@oregonstate.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sandra Uesugi, RN, BSN, MS</last_name>
      <phone>541-737-3594</phone>
      <email>lpi.research@oregonstate.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 3, 2023</study_first_submitted>
  <study_first_submitted_qc>March 16, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2023</study_first_posted>
  <last_update_submitted>March 16, 2023</last_update_submitted>
  <last_update_submitted_qc>March 16, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon State University</investigator_affiliation>
    <investigator_full_name>Laura Beaver</investigator_full_name>
    <investigator_title>Research Associate</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Dysbiosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participant data will not be shared with other researchers without IRB approval.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

